Case report| Volume 42, 102074, July 2020

MOG-antibody-associated hypertrophic pachymeningitis


      • MOG-associated disease (MOGAD) is a distinct disease entity.
      • The whole spectrum of the disease is not yet fully defined.
      • We report an adult case of MOGAD with hypertrophic pachymeningitis (HP).
      • Clinicians should consider testing for MOG-antibody in cases with HP.



      The clinical spectrum of myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease is expanding.


      To describe an unusual case of MOG-antibody-associated hypertrophic pachymeningitis (HP).


      Case study.


      A 57-year-old female presented with a generalised seizure on a background of 3 months history of progressive cognitive decline and behavioural changes. Brain Magnetic Resonance Imaging (MRI) revealed widespread pachymeningeal enhancement and hyperintense signal in both hippocampi. Cerebrospinal Fluid (CSF) examination was normal. The patient was found positive for MOG-antibody. She clinically improved with steroids and the MRI abnormalities completely resolved.


      Clinicians might consider testing for MOG-antibody in cases with HP.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baba T.
        • Shinoda K.
        • Watanabe M.
        • et al.
        MOG antibody disease manifesting as progressive cognitive deterioration and behavioural changes with primary central nervous system vasculitis.
        Mult. Scler. Relat. Disord. 2019; 30: 48-50
        • Jarius S.
        • Paul F.
        • Aktas O.
        • et al.
        MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
        J. Neuroinflamm. 2018; 15: 134
        • Jurynczyk M.
        • Messina S.
        • Woodhall M.R.
        • et al.
        Clinical presentation and prognosis in MOG-antibody disease: a UK study.
        Brain. 2017; 140 (3128-3128)
        • Kupersmith M.J.
        • Martin V.
        • Heller G.
        • et al.
        Idiopathic hypertrophic pachymeningitis.
        Neurology. 2004; 62: 686-694
        • Papathanasiou A.
        • Tanasescu R.
        • Davis J.
        • et al.
        MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity.
        J. Neurol. 2020; 267: 359-368
        • Reindl M.
        • Schanda K.
        • Woodhall M.
        • et al.
        International multicenter examination of MOG antibody assays.
        Neurol. Neuroimmunol. Neuroinflamm. 2020; 7: e674
        • Salama S.
        • Khan M.
        • Pardo S.
        • et al.
        MOG antibody-associated encephalomyelitis/encephalitis.
        Mult. Scler. 2019; 25: 1427-1433
        • Uchigami H.
        • Arai N.
        • Sekiguchi M.
        • et al.
        Anti-myelin oligodendrocyte glycoprotein antibody-positive acute disseminated encephalomyelitis mimicking limbic encephalitis: a case report.
        Mult. Scler. Relat. Disord. 2019; 38101500
        • Ueno T.
        • Kon T.
        • Kaneko K.
        • et al.
        Contrast enhancement of hypertrophic dura mater in MOG antibody-associated disease.
        Neurology. 2019; 93: 271-272
        • Wang L.
        • ZhangBao J.
        • Zhou L.
        • et al.
        Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China.
        Eur. J. Neurol. 2019; 26: 168-174
        • Waters P.
        • Woodhall M.
        • O’Connor K.C.
        • et al.
        MOG cell-based assay detects non-MS patient with inflammatory neurologic disease.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e89
        • Waters P.
        • Komorowski L.
        • Woodhall M.
        • et al.
        A multicentre comparison of MOG-IgG cell-based assays.
        Neurology. 2019; 92: e1250-e1255